UBS Maintains Buy on Tenet Healthcare, Raises Price Target to $217
Portfolio Pulse from Benzinga Newsdesk
UBS analyst A.J. Rice has maintained a Buy rating on Tenet Healthcare (NYSE:THC) and increased the price target from $197 to $217.
October 30, 2024 | 2:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst A.J. Rice has maintained a Buy rating on Tenet Healthcare and increased the price target from $197 to $217, indicating a positive outlook.
The increase in price target from $197 to $217 by UBS suggests a positive outlook for Tenet Healthcare, likely leading to a short-term increase in stock price as investors react to the analyst's confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100